Title: Effects of tripterygium wilfordii combined with methotrexate on bone metabolism and levels of inflammatory factors in serum in patients with rheumatoid arthritis
Abstract:Objective
To investigate the effects of tripterygium wilfordii combined with methotrexate on bone metabolism and levels of macrophage colony stimulating factor (M-CSF), interleukin-6 (IL-6) and inter...Objective
To investigate the effects of tripterygium wilfordii combined with methotrexate on bone metabolism and levels of macrophage colony stimulating factor (M-CSF), interleukin-6 (IL-6) and interleukin-8 (IL-8) in serum in patients with rheumatoid arthritis.
Methods
A total of 108 patients treated in Zhengzhou People’s Hospital from May 2018 to July 2019 were divided into the conventional group and combined group by random number table method, with 54 cases in each group. Patients in the conventional group were only given methotrexate, while patients in the combined group were treated with tripterygium wilfordii combined with methotrexate. The symptoms, signs, bone metabolism indicators and serum cytokine levels of the two groups were compared before and after treatment. Moreover, the treatment effects of the two groups were compared.
Results
The effective rate of the combined group was 81.48% (44/54), which was significantly better than the 66.67% (36/54) of the conventional group (P 0.05). After treatment, the visual analogue scale (VAS) score of the combined group was 0.99±0.37, and the morning stiffness time was (21.43±6.42)min, which were significantly better than the 1.28±0.46 and (29.57±7.08)min of the conventional group (P<0.05). After treatment, the joint swelling number, 20 meters walking time of the combined group were improved, and they were superior to the indexes of the conventional group (P<0.05). The levels of human osteocalcin N-terminal in the middle (N-MID), β-crosslaps (β-CTX) and total procollagen type 1 amino-terminal propeptide (T-P1NP) in the combined group were (21.34±5.14)ng/ml, (0.56±0.12)ng/ml, (37.05±7.61)ng/ml, respectively; M-CSF, IL-6 and IL-8 in the combined group were (10.14±2.48)mg/L, (2.46±0.45)ng/ml, (56.21±12.73)ng/ml, respectively, which were significantly improved and better than those of the conventional group (P<0.05).
Conclusions
In the treatment of rheumatoid arthritis, tripterygium wilfordii combined with methotrexate can effectively improve the clinical efficacy and help to improve the bone metabolism indexes and expression of M-CSF, IL-6 and IL-8.
Key words:
Tripterygium wilfordii; Immunosuppressant; Methotrexate; Rheumatoid arthritis; Bone metabolismRead More
Publication Year: 2020
Publication Date: 2020-02-10
Language: en
Type: article
Access and Citation
Cited By Count: 2
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot